Fangda Partners beefs up biopharmacy, aircraft leasing practices

Fangda hires Henry He and Judy Tan
From left: Judy Tan, Henry He

Fangda Partners has hired Shanghai-based Henry He and Guangzhou-based Judy Tan as partners to grow the firm’s biopharmaceutical and aircraft leasing business.

Henry He, who was a board secretary and head of legal at CStone Pharmaceuticals, specialises in life sciences and healthcare matters, especially technology licensing (introductions and grants), asset acquisitions and divestitures, drug discovery collaborations and option trading.

He has advised on more than 15 cross-border licensing and co-development transactions with global pharmaceutical companies during the past five years of his in-house career, including representing CStone Pharmaceuticals to complete a USD1.15 billion global out-licensing partnership with EQRx for two key immune checkpoint inhibitors. Other collaborations included Pfizer, LegoChem Biosciences, Hengrui Medicine, Blueprint Medicines and others.

Before joining CStone Pharmaceuticals, he practised at Cooley and Baker McKenzie. He is qualified in the PRC and Massachusetts.

Tan, a banking and financing specialist, has been involved in the aviation sector for more than 20 years and is well-versed in the purchase, disposal, financing and leasing of various aircraft, including Boeing, Airbus and Bombardier planes, business jets and helicopters.

She advised Natixis on a USD500 million 30-aircraft leasing project with ICBC Aviation Leasing in 2018, handling matters involving French lease taxes and China’s bonded area.

Tan practised at the US law firm Condon & Forsyth in 2000, and three years later moved to Hong Kong, where she worked at Norton Rose Fulbright, Allen & Overy, and William KK Ho & Ko from 2003 to 2008. Before moving to Fanda Partners, Tan was a partner at JunZeJun Law Offices.